期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肺动脉高压的免疫调节治疗 被引量：2

Treatment status of immunotherapy for pulmonary arterial hypertension
暂未订购
导出
摘要 肺动脉高压是临床上常见的疾病,其发病机制尚未完全清楚。免疫因素在肺动脉高压的发病机制中起重要作用。免疫抑制疗法为肺动脉高压治疗提供了新的途径。本文就机体免疫紊乱对肺动脉高压的影响机制及其免疫调节治疗的临床应用及研究现状进行综述。 Pulmonary hypertension is a common disease,and the pathogenesis of it is not entirely clear.Immune factors play an important role in pathogenesis of pulmonary hypertension.The immunesuppressive therapy provides a new way for pulmonary hypertension treatment.This article summarizes the mechanisms and immunotherapy of pulmonary hypertension.
作者 刘明伟 李岚
机构地区 昆明市延安医院呼吸二科
出处 《实用药物与临床》 CAS 2011年第1期63-66,共4页 Practical Pharmacy and Clinical Remedies
关键词 肺动脉高压 免疫机制 免疫细胞 免疫分子 Pulmonary arterial hypertension Immunologic mechanism Immune cell Immune molecules
分类号 R543 [医药卫生—心血管疾病]
  • 相关文献

参考文献28

  • 1Ghofrani HA, Wilkins MW, Rich S. Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension [ J ]. Circulation, 2008,118 ( 11 ) : 1195-1201.
  • 2Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension:updated ACCP evidence- based clinical practice guidelines[J ]. Chest, 2007,131 ( 6 ) : 191741928.
  • 3Tuder RM, Groves B, Badesch DB, et al. Exuberant endothelial cell and elements of inflammation are presentin plexiform lesions of pulmonary hypertension [ J]. Am J Pathol, 1994,144 (2) :275-285.
  • 4Guihot A, Dupin N, Mareelin AG, et al. Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma [J].J Infect Dis, 2006, 194 ( 8 ) : 1078- 1088.
  • 5Boyer O, Saadoun D, Abriol J, et al. CD4 ^+ CD25 ^+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryo-globulinemia vasculitis [J ]. Blood,2004,103 ( 9 ) : 3428-3430.
  • 6Machado RD, Aldred MA, James V, et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension[ J]. Hum Murat,2006,27(2) :121-132.
  • 7Daley E, Emson C, Guignabert C, et al. Pulmonary arterial remodeling induced by a Th2 immune response[J].J Exp Med, 2008,205 ( 2 ) :361-372.
  • 8Damas JK, Otterdal K, Yndestad A, et al. Soluble CIMO ligand in pulmonary arterial hypertension:possible pathogenic role of the interaction between platelets and endothelial cells[ J]. Circulation, 2004,110 ( 8 ) :99941005.
  • 9Hoshino T, Kato S, Oka N, et al. Pulmonary inflammation and emphysema:role of the cytokines IL-18 and IL-13[ J]. Am J Respir Crit Care Med,2007,176( 1 ) :49-62.
  • 10陈海燕,白元.肺动脉高压的治疗新策略[J].实用医学杂志,2008,24(20):3455-3457. 被引量：5

二级参考文献55

  • 1潘殿柱,李永春.阿托伐他汀对低氧大鼠肺血管重建的影响[J].中国全科医学,2005,8(14):1149-1151. 被引量：10
  • 2夏秀琼,程德云,苏巧俐,陈小菊,杨莉.斯伐他汀抑制血管紧张素-Ⅱ受体1的表达,预防大鼠低氧性肺动脉高压[J].中国呼吸与危重监护杂志,2007,6(3):213-216. 被引量：8
  • 3Schermuly R T, Dony E, Ghofrani H A, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition [J].J Clin Invest,2005,115(10): 2811-2821.
  • 4Ghofrani H A, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension [J]. N Engl J Med,2005,353 (13) : 1412-1413.
  • 5Souza R, Sitbon O, Parent F, et al. Long term imatinib treatment in pulmonary arterial hypertension [ J ]. Thorax, 2006,61 (8) : 736.
  • 6Kerkela R, Grazette L, Yacobi R, et al. Carcliotoxicity of the cancer therapeutic agent imatinib mesylate [J]. Nat Med,2006, 12 (8):908-916.
  • 7Kao P N. Simvastatin treatment of pulmonary hypertension: observational case series [J]. Chest,2005,127(4): 1446-1452.
  • 8Wang X X, Zhang F R, Shang Y P, et al. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial [J]. J Am Coll Cardiol,2007,49( 14): 1566-1571.
  • 9D'Alonzo G E, Barst R J, Ayres S M, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry [J]. Ann Intern Med, 1991,115(5) :343-349.
  • 10Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension., a double-blind, randomized, placebocontrolled trial [ J ]. Am J Respir Crit Care Med, 2002,165 (6) : 800-804.

共引文献49

同被引文献12

  • 1Simonneau G, Galie N,Rubin LJ, et al. Clinical classification ofpulmonary hypertension [J]. J Am Coll Cardiol, 2004(12 Suppl S),43: 5S-12S.
  • 2Vassilion UA, Mogssakis I,Boki KA, et al. Is the heart affected inprimary Sjogren ’ s syndrome. An echocardiographic study [J]. ClinExp Rheumatol, 2008, 26(1): 109-112.
  • 3Mittoo S,Jacob T, Craiq A, et al. Treatment of pulmonaryhypertension in patients with connective tissue disease andinterstitial lung disease[J]. Can Respir J,2010, 17(6):282-286.
  • 4Nakagawa N, Osanais,Ide H, et al. Severe pulmonary hgpertensionassociated with SjOgren1 s syndrome [J]. Intern Med, 2003, 42( 12):1248-1252.
  • 5Gonzalez -Lopez L, Cardona -Munoz EG,Celis A, et al. Therapywith intermittent pulse eyelophosphamide for pulmonaryhypertension associated with systemic lupus erythematosus [J]_Lupus, 2004, 13(2): 105-112.
  • 6Leary PJ, Kurtz CE, Hough CL, et al. Three-dimensional analysisof right ventricular shape and function in pulmonary hypertension[J].Pulm Circ, 2012,2(1):34-40.
  • 7叶任高内科学[M].第五版.北京:人民卫生出版社.2000:310-312.
  • 8Cool CD, Stewart JS, Werahera P, et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers: Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth.The American journal of pathology,1999,155(2): 411-419.
  • 9蔡柏蔷.慢性阻塞性肺疾病发病机制的新进展[J].中华内科杂志,2000,39(3):204-206. 被引量：67
  • 10毛山,胡学宁,王崇全,王治校,詹中群,何朝荣.低分子肝素钙联合氯吡格雷对肺心病急性加重期血液高凝状态及心肺功能的影响[J].临床和实验医学杂志,2012,11(10):756-757. 被引量：13

引证文献2

二级引证文献5

实用药物与临床
2011年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部